A phase III trial of bevasiranib, a treatment for wet age-related macular degeneration and the most advanced RNAi drug candidate in human testing, has been halted early after being deemed "unlikely" to meet its primary endpoint, the therapy's developer said last week.

According to Opko Health, the trial's independent data-monitoring committee had recommended ending the study after reviewing preliminary data, which "showed activity of bevasiranib … [but] indicated that the trial, as structured, was unlikely to meet its primary endpoint."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.